

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit (fluorescent immunochromatography) and Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit (fluorescent immunochromatography) have obtained the medical device registration certificates from the Hebei Provincial Drug Administration of China.

Full-range C-reactive protein (hsCRP + conventional CRP) Test Kit is used for in vitro quantitative detection of C-reactive protein levels in whole blood, serum and plasma samples from human, and is clinically used as an adjunct to the diagnosis of non-specific inflammation and cardiovascular diseases. Serum Amyloid A / C-reactive protein (SAA/CRP) Test Kit is used for in vitro quantitative detection of serum amyloid A (SAA) and C-reactive protein (CRP) levels in human serum/plasma/whole blood samples, and is clinically used as an adjunct to the diagnosis of non-specific inflammation. Successive approvals of multiple test kits have created a new track for the Group’s medical device products.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 6 May 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.